Vaccines and immunotherapeutics derived from the human immunodeficiency virus (HIV) transactivator of transcription protein for the treatment and prevention of HIV disease
US8323928B2 · kind B2 · utility
0Cited by
3References
4Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Mar 24, 2006 |
| Grant date | Dec 4, 2012 |
| Priority date | — |
| Expiry date | Mar 24, 2026 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/162
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Anti-lentivirus vaccines and immunotherapeutics and methods for preparing and using same are disclosed. The vaccines and immunotherapeutics are produced using non-immunosuppressive lentivirus trans-activator of transcription (Tat) proteins. An associated in vitro ultra-sensitive macrophage Tat bioassay is disclosed for assessing the immunosuppressive qualities of the lentivirus Tat preparations of the present invention. Additionally, a related long-term T4 cell propagation system for characterizing lentivirus Tat is also disclosed. The present invention has additional utility in the treatment and prevention of AIDS.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.